Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-17T11:23:07.741Z Has data issue: false hasContentIssue false
  • English
  • Français

Role of dopamine in non-depressed patients with a history of suicide attempts

Published online by Cambridge University Press:  16 April 2020

W. Pitchot ,
M. Hansenne  and
M. Ansseau
W. Pitchot*
Affiliation:
Psychiatric Unit, CHU Sart Tilman, B-4000Liège, Belgium
M. Hansenne
Affiliation:
Psychiatric Unit, CHU Sart Tilman, B-4000Liège, Belgium
M. Ansseau
Affiliation:
Psychiatric Unit, CHU Sart Tilman, B-4000Liège, Belgium
*
*Correspondence and reprints.
Get access

Summary

Several data are available about the implication of the dopaminergic system in the control of inward-directed aggression. Previously, we suggested an involvement of D2-dopaminergic function in the expression of suicidal behavior by demonstrating a smaller growth hormone (GH) response to apomorphine, a dopaminergic agonist, in depressed patients with a history of suicide attempts in comparison to non-attempters. In the present study, in order to test this hypothesis, GH responses to intravenous apomorphine were measured in non-depressed patients with a history of suicide attempts. The study was performed in 17 non-depressed male patients with a score less than 12 on the 17-item HAMD. The patients were subgrouped into suicide attempters (N = 7) and non-attempters (N = 10). Mean GH peak responses to apomorphine differed significantly between suicide attempters and non-attempters: (mean ± SD) for GH peak, 10.4 ± 8.2 ng/mL vs 27.3 ± 13.1 ng/ml, F = 9.0, P = 0.009. In conclusion, dopaminergic disturbances seem to play a role in the biology of inward-directed aggression in non-depressed patients.

Keywords

depressiondopaminemonoaminesuicide
Type
Short Communications
Information
European Psychiatry , Volume 16 , Issue 7 , November 2001 , pp. 424 - 427
Copyright
Copyright © European Psychiatric Association 2001

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Agren, H.Life at risk: markers of suicidality in depression. Psychiat Dev 1983; 1: 87–104.Google ScholarPubMed
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd. ed. rev. Washington DC: APA; 1987.Google Scholar
Ansseau, MScheyvaerts, MDoumont, APoirrier, RLegros, JJFranck, G.Concurrent use of REM latency, dexamethasone suppression, clonidine and apomorphine tests as biological markers of endogenous depression. Psychiatry Res 1984; 12: 261–72.CrossRefGoogle ScholarPubMed
Arranz, BBlennow, KEriksson, AMansson, JEMarcusson, J.Serotonergic, noradrenergic, and dopaminergic measures in suicide brains. Biol Psychiatry 1997; 41: 1000–9.CrossRefGoogle ScholarPubMed
Beskow, JGottfries, CRoos, BWinblad, B.Determination of monoamine and monoamine metabolites in the human brain: postmortem studies in a group of suicides and in a control group. Acta Psychiatr Scand 1976; 53: 7–20.CrossRefGoogle Scholar
Bowden, CCheetham, SCLowther, SKatona, CLECrompton, MRHorton, RW.Reduced dopamine turnover in the basal ganglia of depressed suicides. Brain Res 1997; 769: 135–40.CrossRefGoogle ScholarPubMed
Crow, TJCross, AJCooper, SJ. et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with alzheimer-type dementia and depression and suicides. Neuropsychopharmacology 1984; 23: 1561–9.Google ScholarPubMed
Engström, GAlling, CBlennow, KRegnéll, GTräskman-Bendz, L.Reduced cerebrospinal HVA concentrations and HVA/5-HIAA ratios in suicide attempters. Monoamine metabolites in 120 suicide attempters and 47 controls. Eur Neuropsychopharmacol 1999; 9: 399–405.CrossRefGoogle ScholarPubMed
Franchimont, P.Le dosage radioimmunologique de l'hormone de croissance humaine. Cah Med Lyon 1968; 44: 887–98.Google Scholar
Hamilton, M.A rating scale for depression. J Neurol Neurosurg Psychiat 1960; 23: 56–62.CrossRefGoogle ScholarPubMed
Laakmann, G.Psychopharmacology and depression research. Berlin: Springer-Verlag; 1990.CrossRefGoogle Scholar
Mann, JJMalone, KM.Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol Psychiatry 1997; 41: 162–71.CrossRefGoogle ScholarPubMed
Montgomery, SAMontgomery, D.Pharmacological prevention of suicidal behavior. J Affective Disord 1982; 4: 291–8.CrossRefGoogle Scholar
Ohmori, TArora, RCMeltzer, HY.Serotonergic measures in suicide brain: the concentration of 5-HIAA, HVA, and tryptophan in frontal cortex of suicide victims. Biol Psychiatry 1992; 32: 57–71.CrossRefGoogle ScholarPubMed
Pitchot, WHansenne, Gonzalez Moreno, AAnsseau, M.Suicidal behavior and growth hormone response to apomorphine test. Biol Psychiatry 1992; 31: 1213–9.CrossRefGoogle ScholarPubMed
Pitchot, WGonzalez Moreno, AHansenne, MAnsseau, M.Growth hormone response to clonidine in nondepressed patients with a history of suicide attempts. Biol Psychiatry 1995; 37: 201–3.CrossRefGoogle Scholar
Pitchot, WHansenne, MGonzalez Moreno, AAnsseau, M.Effect of previous antidepressant therapy on the growth hormone response to apomorphine. Neuropsychobiology 1995; 32: 19–22.CrossRefGoogle ScholarPubMed
Pitchot, WReggers, JPinto, EHansenne, Fuchs, SPirard, S. et al. Reduced dopaminergic activity in depressed suicides. Psychoneuroendocrinology 2001; 26: 331–3.CrossRefGoogle ScholarPubMed
Roy, AAgren, APickar, DLinnoila, MDoran, ACutler, N. et al. Reduced CSF concentrations of homovanillic acid and homovanillic acid to 5-hydroxyindolacetic acid ratios in depressed patients: Relationship to suicidal behavior and dexamethasone nonsuppression. Am J Psychiatry 1986; 143: 1539–45.Google Scholar
Roy, ADe Jong, JLinnoila, M.Cerebrospinal fluid monoamine metabolites and suicidal behavior in depressed patients: a 5-years follow-up study. Arch Gen Psychiatry 1989; 46: 609–12.CrossRefGoogle Scholar
Roy, AKaroum, FPollack, S.Marked reduction in indexes of dopamine metabolism among patients with depression who attempt suicide. Arch Gen Psychiatry 1992; 49: 447–50.CrossRefGoogle ScholarPubMed
Roy, APollack, S.Are cerebrospinal fluid or urinary monoamine metabolite measures stronger correlates of suicidal behavior in depression?. Neuropsychobiology 1994; 29: 164–7.CrossRefGoogle ScholarPubMed
Träskman, LAsberg, MBertilsson, LSjöstrand, L.Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry 1981; 38: 631–6.CrossRefGoogle ScholarPubMed
Träskman-Bendz, LAlling, CAlsén, MRegnéll, GSimonsson, PÖhman, R.The role of monoamines in suicidal behavior. Acta Psychiatr Scand 371(Suppl)1993 45–47.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.